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Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62 S31Conclusions: The prolonged intra-articular inhibition of IL-1 reduced
the severity of arthritic changes in both cartilage and joint tissue.
However, the inhibition of TNF-a resulted in detrimental bone
morphological changes, loss of cartilage, and inﬂammation of joint
tissue. This study shows a novel reduction in post-trauma inﬂammation
and demonstrates utility for an injectable drug depot for clinical intra-
articular applications in the treatment of joint trauma.
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IDENTIFICATION OF THE PATIENTS WHO RESPOND SAFELY AND
OPTIMALLY TO INTERVENTION WITH BIOLOGICS; LESSON LEARNED
FROM RHEUMATOID ARTHRITIS
A.-C. Bay-Jensen, A. Siebuhr, I. Byrjalsen, C. Christiansen, M.A.
Karsdal. Nordic BioSci. A/S, Herlev, Denmark
Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized debilitating joint destruction, if not treated aggressively
in the patient in most need of treatment. Personalized health care is
needed and tested in RA, as response rates are low compared to the
potential side effects and cost of treatment. Thus lessons on patient
segregation can be learned and used in other joint diseases, such as
osteoarthritis (OA). We investigated whether tissue-speciﬁc, serum-
based biomarkers measured at baseline or after 1 dose could identify
“super responders” to 4 mg/kg tocilizumab in patients with moderate
to severe RA on a methotrexate background enrolled in the LITHE
study.
Methods: The LITHE biomarker study (n¼740) was a phase III study of 4
and 8mg/kg TCZ in combinationwithMTX. Patients were separated into
ACR50 (week 52) responders and non-responder and serum biomarkers
were measured at baseline and week 4. Following tissue-speciﬁc
biomarkers were measured; C3M (synovial turnover), CRPM (connec-
tive tissue inﬂammation), C2M (cartilage degradation), CTx (bone
resorption), osteocalcin (bone formation), CRP (acute phase reactant)
and MMP3 (proteolytical activity). ROC was use to ﬁnd the optimal cut-
offs for the biomarkers at baseline and change from baseline to week4.
CART analysis was used to segregate patients and 2x2 contingency test
was used for identifying response rates.
Results: A simple combination of 4 baseline markers (C1M, C3M, MMP-
3 and CRPM) increased the response rates (ACR50 at week 52) from 27
to 54%, while restricting the patient population to 22 %. When including
the change from baseline to 4 weeks of cartilage degradation or bone
formation, patient beneﬁt was enriched to 64 %, while allowing
continued treatment of 17% of patients and referral of 92% of the non-
responders earlier to other possible interventions (ﬁgure).
Conclusions: By using a combination of simple serological markers,
response rates were more than doubled in so-called “IL-6 super
responders”. This may assist in identiﬁcation of the patients, in any
inﬂammatory disease, who respond most optimally to given interven-
tions, with fewer AEs, and thus provide a stronger risk/beneﬁt/cost
value proposition to patients and payers.Ă45
IDENTIFICATION OF FIBROBLAST GROWTH FACTOR-18 AS
A MOLECULE TO PROTECT AND REGENERATE ARTICULAR CARTILAGE
Y. Mori y, T. Saito y, C.H. Ladel z, H. Guehring z, U.-i. Chung y, H.
Kawaguchi y. y Sensory & Motor System Med., Univ. of Tokyo, Tokyo,
Japan; zMerck Serono Res., Darmstadt, GermanyPurpose: Aiming at the disease-modifying treatment of osteoarthritis
(OA), we sought to identify genes that maintain the homeostasis of
adult articular cartilage and regenerate its lesions by gene expression
proﬁle analyses.
Methods:We initially performed two sets of microarray analyses. First,
to identify genes involved in maintenance of articular cartilage, we
compared gene expression proﬁles between adult articular (AA) and
adult growth plate (AG) cartilages in 10-week-old rats. Second, to
identify genes involved in regeneration of articular cartilage, we
compared the proﬁles between infant superﬁcial (IS) and infant deep
(ID) layers of epiphyseal cartilage in 6-day-old rats. For genes which
were up-regulated 10-fold both in AA than AG and in IS than ID, we
performed real-time RT-PCR for the conﬁrmation. In vivo expression of
the identiﬁed gene was examined by immunohistochemistry of artic-
ular and growth plate cartilage of 14-week-old rats. The therapeutic
effect was examined in the experimental OA model by surgical induc-
tion of instability in the knee joints of adult rats. To learn the underlying
mechanism, the protective ability of articular cartilage was assessed by
measuring the amount of sulfated glycosaminoglycan (sGAG) released
into the medium in the ex vivo culture of bilateral femoral heads of 3-
week-old mice. Proliferation and migration were analyzed in the
cultures of mouse articular chondrocytes using Cell Counting Kit-8 and
Oris Cell Migration assay systems, respectively. Expression levels of
catabolism-related factors (Mmp9, Mmp13, Adamts4, Adamts5, Timp1,
Timp2, and Timp3) and anabolism-related factors (Col2a1 and aggre-
can) in the cultures of mouse femoral heads and mouse articular
chondrocytes were analyzed by real-time RT-PCR.
Results: Microarray analyses revealed that 40 and 186 genes had 10-
fold higher expression ratios of AA/AG and IS/ID, respectively, and 16
genes showed 10-fold of both AA/AG and IS/ID ratios. The ratios of the
16 genes were conﬁrmed to be 10 fold by real-time RT-PCR analysis.
Among them three genes were expressed more strongly in AA than in
IS. In these three genes, ﬁbroblast growth factor-18 (Fgf18) was the
extracellular and secreted factor of which the AA/AG ratio was the
highest in the microarray analysis. Immunohistochemistry showed that
Fgf18 was strongly expressed in the articular cartilage chondrocytes of
adult rats but was hardly detected in the growth plate cartilage. In the
rat surgical OA model, a once-weekly intra-articular injection of
recombinant human (rh) FGF18 given 3 weeks post-surgery prevented
cartilage degeneration in a dose-dependent manner at 6 and 9 weeks
after surgery, with a signiﬁcant effect at 10 mg/week of rhFGF18. As an
underlying mechanism, rhFGF18 suppressed the sGAG release into the
culture medium in the ex vivo culture of mouse femoral heads.
Furthermore, rhFGF18 accelerated proliferation and migration of
cultured mouse articular chondrocytes. Among catabolic and anabolic
factors, rhFGF18 decreased Adamts4 and increased Timp1 expressions
in the cultures of mouse femoral heads and murine articular chon-
drocytes, while it decreased Col2a1 and aggrecan expressions in both
cultures.
Conclusions: The present gene expression proﬁling analysis identiﬁed
Fgf18 as a molecule to protect and regenerate adult articular cartilage,
causing prevention of OA development by the intra-articular injection
in a rat model. This effect may be mediated by inhibition of cartilage
catabolism, and acceleration of proliferation and migration of articular
chondrocytes, indicating a possible disease-modifying OA treatment.46
MICRORNAS ARE PROGNOSTIC MARKERS FOR THE CHONDROGENIC
POTENTIAL OF MSCS
N. Georgi y, H. Taipaleenmaki z, A. van Wijnen z, N. Groen y, K. Janaeczek-
Portalska y, C.A. van Blitterswijk y, J. de Boer y, J.N. Post y, M.
Karperien y. yUniv. of Twente, Enschede, Netherlands; zMayo Clinic,
Rochester, MN, USA
Purpose: The capacity of mesenchymal stromal cells (MSCs) to differ-
entiate into chondrocytes as well as to function as trophic mediators
restoring joint homeostasis make them a promising cell source for
a disease modifying treatment in osteoarthritis. MSCs can be easily
harvested from various locations of the body, including amongst others
bone marrow, periosteum, synovium, synovial ﬂuid, adipose tissue,
buccal fat pad, infrapatellar fat pad and osteoarthritic cartilage. MSCs
are a heterogeneous cell population and large inter-donor variation
with respect of the chondrogenic potential of these cells has been re-
ported which may hamper clinical application. Presently, prognostic
